Last reviewed · How we verify
NCT05848128
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Phase 3 trial testing 5% Tavilermide ophthalmic solution in Dry Eye Syndromes in 642 participants. Completed in 11 May 2024.
11 May 2024
Quick facts
| Lead sponsor | Mimetogen Pharmaceuticals USA, Inc. |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 642 |
| Start date | 28 June 2023 |
| Primary completion | 11 May 2024 |
| Estimated completion | 11 May 2024 |
| Sites | 29 locations across United States |
Drugs / interventions tested
- 5% Tavilermide ophthalmic solution — full drug profile →
- Vehicle ophthalmic solution — full drug profile →
Conditions studied
- Dry Eye Syndromes — all drugs for Dry Eye Syndromes →
- Dry Eye Disease — all drugs for Dry Eye Disease →
- Kerato Conjunctivitis Sicca — all drugs for Kerato Conjunctivitis Sicca →
Sponsor
Mimetogen Pharmaceuticals USA, Inc. — full company profile →
Who can join
18 and older, any sex, with Dry Eye Syndromes or Dry Eye Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to compare the efficacy and safety of 5% tavilermide ophthalmic solution to placebo for the treatment of the signs and symptoms of dry eye disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.
Xiao W, Jiang W, Chen Z, Huang Y, et al · · 2025 · cited 144× · PMID 40038239 · DOI 10.1038/s41392-024-02107-5
Verify or expand the search:
- PubMed search for NCT05848128
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dry Eye Syndromes
Currently open trials in the same condition.
- NCT07412860 — Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hy · NA · recruiting
- NCT06913504 — Comparison Of Blue Light Filter Feature and Blue Blocking Lenses in Digital Device Users With Dry Eye Patients · NA · active not recruiting
- NCT06913465 — The Impact of Hypothyroidism on Tear Production and Dry Eye Symptoms: Implications for Optometric Care · active not recruiting
- NCT06831253 — Efficacy of Platelet-Rich Plasma Injection in Dry Eye Syndrome · NA · recruiting
- NCT06220474 — Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD · NA · recruiting
Other Mimetogen Pharmaceuticals USA, Inc. trials
Trials by the same sponsor.
- NCT03925727 — Tavilermide Ophthalmic Solution for the Treatment of Dry Eye · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05848128 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mimetogen Pharmaceuticals USA, Inc.
- Last refreshed: 10 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05848128.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing